News Roche's Ocrevus MS drug approved in EU Already a big hit in the US, Ocrevus set to make debut in EU.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Merck KGaA/Pfizer's Bavencio fails in stomach cancer trial Merck KGaA and Pfizer’s cancer immunotherapy Bavencio has disappointed in a hard to treat late-stage gastric cancer trial, failing to extend survival compared to chemotherapy.
News Apitope announces IPO to fund MS drug development Biotech Apitope plans to float on the Brussels stock exchange to raise funds to develop a potential new MS drug.
News Regulators finally back Merck KGaA oral MS drug A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.
News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
